- Trial Phase
- Phase 2
- Time to Market
- Unknown for CSU — the program is still Phase 2 with no Phase 3 or filing announced. For the SCID (rare pediatric) program, a BLA-path update is slated for Q1 2027, implying a potential filing/approval no earlier than 2027-2028 at best; there is no PDUFA date on file.
- Why 5/10
- The next hard, dated catalyst is the Q1 2027 briquilimab BLA-path update (per Jasper's Q2 2026 earnings commentary), plus an imminent but undated Phase 2 CSU readout from a study that completed July 8, 2026 with results still unposted; impactScore is 5 because briquilimab is now a secondary asset of a combined company led by Kira's KP-104 (legacy Jasper holders own only ~6.68%), and the dated catalyst is a filing-path update, not a PDUFA or pivotal binary.
Watch for the pending Phase 2 chronic-spontaneous-urticaria (CSU) topline from NCT06162728 (87 patients, trial completed July 2026, results not yet posted) — it is the only near-term, non-dated binary tied directly to briquilimab. Beyond that, track the Q1 2027 BLA-path update for the rare-pediatric SCID program, since a Priority Review Voucher there is the trigger for a $30M CVR payment to legacy Jasper holders by Dec 31, 2028. Note that JSPR is now effectively Kira Pharmaceuticals' vehicle (KP-104 lead, $132M PIPE, legacy holders ~6.68%), so briquilimab-specific news moves the stock less than it did pre-merger.
Price Chart
Executive Summary
Briquilimab is Jasper Therapeutics' (Nasdaq: JSPR) anti-c-Kit antibody for mast-cell-driven diseases (chronic spontaneous urticaria, CIndU, asthma) and SCID conditioning. The stock has been transformed in 2026: after a June 2026 strategic-alternatives review at ~$23M market cap, Jasper closed an all-stock acquisition of Kira Pharmaceuticals with a $132M PIPE, leaving legacy Jasper holders at only ~6.68% of the combined company and making Kira's KP-104 the pipeline lead; legacy holders received non-tradeable CVRs worth a $30M payout only if the FDA issues a Priority Review Voucher for briquilimab by Dec 31, 2028. The most immediate briquilimab event is an imminent Phase 2 CSU readout (trial completed July 8, 2026, results unposted), with a dated BLA-path update flagged for Q1 2027.
How It Works
Briquilimab is an antibody drug that targets a protein on cells called c-Kit (CD117). It is designed to deplete or dampen mast cells — the immune cells that release histamine and drive allergic-type reactions such as hives (urticaria) — as a potential treatment for chronic spontaneous urticaria, chronic inducible urticaria and asthma. In its rare-pediatric SCID program it is used as a conditioning agent ahead of a stem-cell transplant in infants born without a functioning immune system; that SCID program is the basis for a potential FDA Priority Review Voucher referenced in the merger documents.
Trial Status
Two Phase 2 trials in chronic urticaria are in SecBot's local ClinicalTrials.gov data: NCT06162728 (dose-escalation, 87 patients, CSU) completed 2026-07-08 with results not yet posted — readout imminent; NCT06736262 (open-label long-term extension, 67 patients, chronic urticaria) is listed as TERMINATED with completion date 2026-07-21. No FDA approval, PDUFA, or FDA action rows exist for briquilimab in the local FDA data; the Q2 2026 earnings analysis flags a briquilimab BLA-path update in Q1 2027.
The Two-Sided Case
Upcoming Catalysts
- Phase 2 CSU topline data from NCT06162728 (completed 2026-07-08; results pending — readout imminent, no fixed date).
- Q1 2027: briquilimab BLA-path update (SCID program) per Q2 2026 earnings commentary.
- Q4 2026: KP-104 Phase 2 interim data — the combined company's lead catalyst, which will dominate JSPR's tape.
- PRV/CVR trigger: FDA issuance of a Priority Review Voucher for briquilimab by Dec 31, 2028 (worth $30M pro-rata to legacy holders).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Jasper Therapeutics, Inc.; Kira Pharmaceuticals Press Release JSPR ·Originating report